Key Highlights
- Shares trading up 10.42% pre-market to $7.84
- Q2 2026 consolidated Revenue of $101.9 million, with Net Income of $26.0 million and Adjusted EBITDA of $58.7 million
- DefenCath sales contributed $66.1 million of net revenue, with the acquired Melinta portfolio adding $35.8 million
- Maintained full-year 2026 revenue guidance of $325 to $345 million and raised Adjusted EBITDA guidance to $125 to $140 million
- Signed a new multi-year DefenCath Supply agreement with a Large Dialysis Operator, completing coverage of all top 5 U.S. dialysis providers
- Anticipates FDA submission of an expanded REZZAYO indication for invasive fungal disease prophylaxis in the third quarter
Shares Rise on Guidance Raise
CorMedix (NASDAQ:CRMD) shares are trading higher in pre-market action Thursday, up 10.42% to $7.84, after the company reported second-quarter 2026 results and raised its full-year Adjusted EBITDA guidance. Consolidated revenue and grant income reached $101.9 million for the quarter, with net income of $26.0 million and Adjusted EBITDA of $58.7 million, reflecting basic and diluted EPS of $0.33 and $0.29, respectively.
CorMedix Therapeutics is a New Jersey-based biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening infectious and inflammatory conditions. Its lead commercial product, DefenCath, taurolidine and heparin, is an FDA-approved antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult hemodialysis patients using central venous catheters, with the company operating as a single drug product segment targeting markets such as hemodialysis, oncology, and total parenteral nutrition, where long-term catheter use poses infection risks.
DefenCath Expands to All Top 5 Dialysis Providers
DefenCath sales contributed $66.1 million of net revenue in the quarter, driven by continued utilization among large outpatient dialysis customers, while the acquired Melinta portfolio contributed $35.8 million. The company signed a new multi-year commercial supply agreement for DefenCath with a Large Dialysis Operator, expanding its commercial contract footprint to include all of the top 5 providers of dialysis services in the U.S. market, with the new operator having commenced ordering and set to begin a pilot in the third quarter.
"CorMedix delivered a strong second quarter, generating $101.9 million in consolidated revenue and $58.7 million of adjusted EBITDA, reflecting continued execution across our business," said Joseph Todisco, CorMedix Chairman and CEO. The company maintained full-year 2026 consolidated revenue guidance of $325 million to $345 million and raised full-year Adjusted EBITDA guidance to $125 million to $140 million, while narrowing cash Operating Expense guidance to $145 million to $155 million. In collaboration with global development partner Mundipharma, the company anticipates FDA submission of an expanded indication for REZZAYO for the prophylaxis of invasive fungal disease in the third quarter, with agency action anticipated in the first half of 2027 if accepted for review.
Conclusion
CorMedix's 10.42% pre-market gain reflects a strong second quarter and raised Adjusted EBITDA guidance, underscored by DefenCath's expanded reach across all of the top 5 U.S. dialysis providers. With an expanded REZZAYO indication submission anticipated in the third quarter and a strengthened Balance Sheet supporting continued commercial execution, the stock's next moves will likely hinge on continued DefenCath adoption as the company navigates the post-TDAPA reimbursement environment.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...